-
![HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS](/abs-image/US/2013/03/14/US20130065914A1/abs.jpg.150x150.jpg)
1.发明申请HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS 审中-公开取代三氮唑[2,3-D]具有MNK1 / MNK2抑制活性的药物组合物的吡嗪公开(公告)号：US20130065914A1
公开(公告)日：2013-03-14
申请号：US13580184
申请日：2011-02-25
Applicant: Armin Heckel , Frank Himmelsbach , Thorsten Lehmann-Lintz , Norbert Redemann , Achim Sauer , Leo Thomas , Phillip Black , Wesley Blackaby , John Danilewicz , Ian Linney , Matthias Austen , Martin Schneider , Kay Schreiter
Inventor： Armin Heckel , Frank Himmelsbach , Thorsten Lehmann-Lintz , Norbert Redemann , Achim Sauer , Leo Thomas , Phillip Black , Wesley Blackaby , John Danilewicz , Ian Linney , Matthias Austen , Martin Schneider , Kay Schreiter
IPC: C07D495/04 , A61P3/10 , A61P3/06 , A61P35/00 , A61P7/00 , A61P25/28 , A61P13/12 , A61P29/00 , A61K31/519 , A61P3/00
CPC classification number: C07D495/04 , A61K31/519 , Y02A50/411
Abstract: The present invention relates to novel thienopyhmidine compounds of general formula (I), pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
Abstract translation: 本发明涉及通式（I）的新型噻吩并嘧啶化合物，包含这些化合物的药物组合物及其用于预防和/或治疗可受到抑制Mnk1和/或Mnk2的激酶活性的疾病的治疗用途 （Mnk2a或Mnk2b）和/或其变体。
-
公开(公告)号：US20110217311A1
公开(公告)日：2011-09-08
申请号：US13034855
申请日：2011-02-25
Applicant: Thorsten LEHMANN-LINTZ , Armin HECKEL , Joerg KLEY , Elke LANGKOPF , Nobert REDEMANN , Achim SAUER , Leo THOMAS , Dieter WIEDENMAYER , Matthias AUSTEN , John DANILEWICZ , Martin SCHNEIDER , Kay SCHREITER , Phillip BLACK , Wesley BLACKABY , Ian LINNEY
Inventor： Thorsten LEHMANN-LINTZ , Armin HECKEL , Joerg KLEY , Elke LANGKOPF , Nobert REDEMANN , Achim SAUER , Leo THOMAS , Dieter WIEDENMAYER , Matthias AUSTEN , John DANILEWICZ , Martin SCHNEIDER , Kay SCHREITER , Phillip BLACK , Wesley BLACKABY , Ian LINNEY
IPC: A61K39/395 , C07D495/04 , A61K31/519 , C07D413/14 , A61K31/5377 , A61K31/496 , A61K31/397 , A61K31/575 , A61K31/573 , A61P3/00 , A61P9/00 , A61P29/00
CPC classification number: C07D495/04
Abstract: The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
Abstract translation: 本发明涉及包含这些化合物的通式药物组合物的新型噻吩并嘧啶化合物及其用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b的激酶活性）的疾病的治疗用途 ）和/或其变体。
-
3.发明授权Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity 有权具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物公开(公告)号：US09012644B2
公开(公告)日：2015-04-21
申请号：US13492188
申请日：2012-06-08
Applicant: Fabio Rancati , Andrea Rizzi , Ian Linney , Wesley Blackaby , Chris Knight
Inventor： Fabio Rancati , Andrea Rizzi , Ian Linney , Wesley Blackaby , Chris Knight
IPC: C07D453/04 , A61K31/47 , C07D401/12 , C07D409/14 , C07D417/12
CPC classification number: C07D401/12 , C07D409/14 , C07D417/12
Abstract: Compounds of formula (I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating and/or preventing broncho-obstructive and inflammatory diseases.
Abstract translation: 式（I）化合物既作为毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂，也可用于治疗和/或预防支气管阻塞性和炎性疾病。
-
4.发明授权Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions 有权含有用于药物组合物的取代烷基的噻吩并嘧啶公开(公告)号：US08853193B2
公开(公告)日：2014-10-07
申请号：US13035023
申请日：2011-02-25
Applicant: Armin Heckel , Frank Himmelsbach , Joerg Kley , Thorsten Lehmann-Lintz , Norbert Redemann , Achim Sauer , Leo Thomas , Dieter Wiedenmayer , Phillip Black , Wesley Blackaby , Ian Linney , Matthias Austen , John Danilewicz , Martin Schneider , Kay Schreiter
Inventor： Armin Heckel , Frank Himmelsbach , Joerg Kley , Thorsten Lehmann-Lintz , Norbert Redemann , Achim Sauer , Leo Thomas , Dieter Wiedenmayer , Phillip Black , Wesley Blackaby , Ian Linney , Matthias Austen , John Danilewicz , Martin Schneider , Kay Schreiter
IPC: C07D495/04 , A61K31/519 , A61K31/5377 , A61K31/56 , A61P29/00 , A61P35/00 , A61P25/28 , A61P13/12 , A61K31/395
CPC classification number: C07D495/04
Abstract: The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
Abstract translation: 本发明涉及包含这些化合物的通式药物组合物的新型噻吩并嘧啶化合物及其用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b的激酶活性）的疾病的治疗用途 ）和/或其变体。
-
5.发明授权Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity 有权具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物公开(公告)号：US08877774B2
公开(公告)日：2014-11-04
申请号：US13492458
申请日：2012-06-08
Applicant: Fabio Rancati , Andrea Rizzi , Gabriele Amari , Matteo Biagetti , Ian Linney
Inventor： Fabio Rancati , Andrea Rizzi , Gabriele Amari , Matteo Biagetti , Ian Linney
IPC: A61K9/00 , C07D211/92 , C07D215/20 , A61K31/4704 , C07D211/46 , A61K31/4525 , A61K31/439 , C07D221/22
CPC classification number: C07D453/02 , A61K9/0075 , A61K9/0078 , A61K9/008 , A61K31/428 , A61K31/439 , A61K31/4525 , A61K31/4704 , A61K31/4709 , C07C213/10 , C07D211/46 , C07D211/92 , C07D215/20 , C07D221/22 , C07D401/12 , C07D451/06 , C07C215/50
Abstract: Compounds of formula(I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive and inflammatory diseases.
Abstract translation: 式（I）化合物既作为毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂，也可用于预防和/或治疗支气管阻塞性和炎性疾病。
-
Patent Agency Ranking
6.发明授权公开(公告)号：US08754079B2
公开(公告)日：2014-06-17
申请号：US13034855
申请日：2011-02-25
Applicant: Thorsten Lehmann-Lintz , Armin Heckel , Joerg Kley , Elke Langkopf , Norbert Redemann , Achim Sauer , Leo Thomas , Dieter Wiedenmayer , Matthias Austen , John Danilewicz , Martin Schneider , Kay Schreiter , Phillip Black , Wesley Blackaby , Ian Linney
Inventor： Thorsten Lehmann-Lintz , Armin Heckel , Joerg Kley , Elke Langkopf , Norbert Redemann , Achim Sauer , Leo Thomas , Dieter Wiedenmayer , Matthias Austen , John Danilewicz , Martin Schneider , Kay Schreiter , Phillip Black , Wesley Blackaby , Ian Linney
IPC: C07D495/04 , A61K31/519 , A61K31/496 , A61K31/5355 , C07D413/12 , A61P25/28 , A61P29/00 , A61P35/00
CPC classification number: C07D495/04
Abstract: The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
Abstract translation: 本发明涉及包含这些化合物的通式药物组合物的新型噻吩并嘧啶化合物及其用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b的激酶活性）的疾病的治疗用途 ）和/或其变体。
-
7.发明授权Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions 有权用于药物组合物的含杂环烷基的噻吩并嘧啶公开(公告)号：US08648068B2
公开(公告)日：2014-02-11
申请号：US13034913
申请日：2011-02-25
Applicant: Thorsten Lehmann-Lintz , Joerg Kley , Norbert Redemann , Achim Sauer , Leo Thomas , Dieter Wiedenmayer , Matthias Austen , John Danilewicz , Martin Schneider , Kay Schreiter , Phillip Black , Wesley Blackaby , Ian Linney
Inventor： Thorsten Lehmann-Lintz , Joerg Kley , Norbert Redemann , Achim Sauer , Leo Thomas , Dieter Wiedenmayer , Matthias Austen , John Danilewicz , Martin Schneider , Kay Schreiter , Phillip Black , Wesley Blackaby , Ian Linney
IPC: C07D495/04 , A61K31/519 , A61K31/5355 , A61P35/00 , A61P25/28 , A61P3/10
CPC classification number: C07D495/04 , C07D519/00
Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
Abstract translation: 本发明涉及包含噻吩并嘧啶化合物的新型药物组合物。 此外，本发明涉及本发明的噻吩并嘧啶化合物用于生产药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a）激酶活性的疾病的用途 或Mnk2b）和/或其变体。
-
8.发明申请HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS 有权用于药物组合物的含有巯基的三烯丙基嘧啶公开(公告)号：US20110212102A1
公开(公告)日：2011-09-01
申请号：US13034913
申请日：2011-02-25
Applicant: Thorsten LEHMANN-LINTZ , Joerg KLEY , Norbert REDEMANN , Achim SAUER , Leo THOMAS , Dieter WIEDENMAYER , Matthias AUSTEN , John DANILEWICZ , Martin SCHNEIDER , Kay SCHREITER , Phillip BLACK , Wesley BLACKABY , Ian LINNEY
Inventor： Thorsten LEHMANN-LINTZ , Joerg KLEY , Norbert REDEMANN , Achim SAUER , Leo THOMAS , Dieter WIEDENMAYER , Matthias AUSTEN , John DANILEWICZ , Martin SCHNEIDER , Kay SCHREITER , Phillip BLACK , Wesley BLACKABY , Ian LINNEY
IPC: A61K31/519 , C07D495/04 , C07D498/04 , A61K31/55 , A61K31/5377 , A61K31/56 , A61K39/395 , A61P3/10 , A61P3/00 , A61P35/00 , A61P25/28 , A61P29/00 , A61P13/12 , A61P3/06
CPC classification number: C07D495/04 , C07D519/00
Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
Abstract translation: 本发明涉及包含噻吩并嘧啶化合物的新型药物组合物。 此外，本发明涉及本发明的噻吩并嘧啶化合物用于生产药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a）激酶活性的疾病的用途 或Mnk2b）和/或其变体。
-
9.发明申请Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands 审中-公开苯并三氮烯衍生物及其作为胃泌素和胆囊收缩素受体配体的用途公开(公告)号：US20070082892A1
公开(公告)日：2007-04-12
申请号：US10556576
申请日：2004-05-12
Applicant: John Spencer , Iain McDonald , Ian Linney
Inventor： John Spencer , Iain McDonald , Ian Linney
IPC: A61K31/5513 , C07D403/02 , C07D255/04
CPC classification number: C07D417/12 , C07D255/04 , C07D403/06 , C07D403/12 , C07D413/12
Abstract: This invention relates to a compound of formula (I). The compound is useful for the treatment of gastrin related disorders.
Abstract translation: 本发明涉及式（I）化合物。 该化合物可用于治疗胃泌素相关疾病。
-
公开(公告)号：US08486953B2
公开(公告)日：2013-07-16
申请号：US13060731
申请日：2009-08-24
Applicant: Matthias Austen , Phillip Black , Wesley Blackaby , John Danilewicz , Ian Linney , Kay Schreiter , Martin Schneider
Inventor： Matthias Austen , Phillip Black , Wesley Blackaby , John Danilewicz , Ian Linney , Kay Schreiter , Martin Schneider
IPC: C07D495/04 , A61K31/381 , A61P9/00
CPC classification number: C07D495/04
Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
Abstract translation: 本发明涉及包含噻吩并嘧啶化合物的新型药物组合物。 此外，本发明涉及本发明的噻吩并嘧啶化合物用于生产药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a）激酶活性的疾病的用途 或Mnk2b）和/或其变体。
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.028 seconds)
